Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
9161736 | Chest | 2005 | 9 Pages |
Abstract
IRM from NBSAP is high, and standard therapies evaluated at the time of this study resulted in poor clinical outcomes. Delayed therapy was not found to be a predictor of adverse outcomes; however, this lack of ability to detect a difference may be a product of small sample size. These findings suggest that newer agents with enhanced clinical activity in NBSAP are needed and that these should be evaluated in a real-world setting, where outcomes of the most ill patients can be assessed.
Keywords
Staphylococcal pneumoniaAPACHEMSSAIRMCARTVAPmethicillin-sensitive Staphylococcus aureusMRSAmethicillin-resistant Staphylococcus aureusBacteremiaICUClassification and regression tree analysisInfectionCross-infectionStaphylococcal infectionsAcute Physiology and Chronic Health EvaluationCritical careHospital mortalityClinical outcomesVentilator-associated pneumonia
Related Topics
Health Sciences
Medicine and Dentistry
Cardiology and Cardiovascular Medicine
Authors
DeRyke PharmD, Lodise PharmD, Rybak PharmD, MS, McKinnon PharmD,